Stem cells can differentiate into blood vessel, bone, heart, cartilage, fat, ligament, liver, muscle, nerve and tendon tissue. Stem cells can currently be obtained from bone marrow and adipose (fat) tissues of dogs, cats and horses. The most common use of stem cell therapy is to treat osteoarthritis in dogs and cats. Other potential uses include repairing bone, ligament and spinal cord injuries, as well as treating kidney and liver diseases, cardiomyopathy (a type of heart disease), and certain skin and intestinal inflammatory diseases.
Highlights
The global Pet Stem Cells market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Pet Stem Cells is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Pet Stem Cells is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Pet Stem Cells in Osteoarthritis Disease is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Pet Stem Cells include GST (Boehringer Ingelheim), EquiCord, VetStem Biopharma, AVSC, Boyalife, Taiwan Pet Valley Advance Biotech Co.,Ltd and Tianjin Bion Medical, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pet Stem Cells, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pet Stem Cells.
The Pet Stem Cells market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Pet Stem Cells market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pet Stem Cells companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
GST (Boehringer Ingelheim)
EquiCord
VetStem Biopharma
AVSC
Boyalife
Taiwan Pet Valley Advance Biotech Co.,Ltd
Tianjin Bion Medical
Segment by Type
Bone Marrow Stem Cells
Adipose Stem Cell
Others
Segment by Application
Osteoarthritis Disease
Immunomodulatory Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pet Stem Cells companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pet Stem Cells Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Bone Marrow Stem Cells
1.2.3 Adipose Stem Cell
1.2.4 Others
1.3 Market by Application
1.3.1 Global Pet Stem Cells Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Osteoarthritis Disease
1.3.3 Immunomodulatory Diseases
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pet Stem Cells Market Perspective (2018-2029)
2.2 Pet Stem Cells Growth Trends by Region
2.2.1 Global Pet Stem Cells Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pet Stem Cells Historic Market Size by Region (2018-2023)
2.2.3 Pet Stem Cells Forecasted Market Size by Region (2024-2029)
2.3 Pet Stem Cells Market Dynamics
2.3.1 Pet Stem Cells Industry Trends
2.3.2 Pet Stem Cells Market Drivers
2.3.3 Pet Stem Cells Market Challenges
2.3.4 Pet Stem Cells Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pet Stem Cells Players by Revenue
3.1.1 Global Top Pet Stem Cells Players by Revenue (2018-2023)
3.1.2 Global Pet Stem Cells Revenue Market Share by Players (2018-2023)
3.2 Global Pet Stem Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pet Stem Cells Revenue
3.4 Global Pet Stem Cells Market Concentration Ratio
3.4.1 Global Pet Stem Cells Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pet Stem Cells Revenue in 2022
3.5 Pet Stem Cells Key Players Head office and Area Served
3.6 Key Players Pet Stem Cells Product Solution and Service
3.7 Date of Enter into Pet Stem Cells Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pet Stem Cells Breakdown Data by Type
4.1 Global Pet Stem Cells Historic Market Size by Type (2018-2023)
4.2 Global Pet Stem Cells Forecasted Market Size by Type (2024-2029)
5 Pet Stem Cells Breakdown Data by Application
5.1 Global Pet Stem Cells Historic Market Size by Application (2018-2023)
5.2 Global Pet Stem Cells Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pet Stem Cells Market Size (2018-2029)
6.2 North America Pet Stem Cells Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pet Stem Cells Market Size by Country (2018-2023)
6.4 North America Pet Stem Cells Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pet Stem Cells Market Size (2018-2029)
7.2 Europe Pet Stem Cells Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pet Stem Cells Market Size by Country (2018-2023)
7.4 Europe Pet Stem Cells Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pet Stem Cells Market Size (2018-2029)
8.2 Asia-Pacific Pet Stem Cells Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pet Stem Cells Market Size by Region (2018-2023)
8.4 Asia-Pacific Pet Stem Cells Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pet Stem Cells Market Size (2018-2029)
9.2 Latin America Pet Stem Cells Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pet Stem Cells Market Size by Country (2018-2023)
9.4 Latin America Pet Stem Cells Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pet Stem Cells Market Size (2018-2029)
10.2 Middle East & Africa Pet Stem Cells Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pet Stem Cells Market Size by Country (2018-2023)
10.4 Middle East & Africa Pet Stem Cells Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GST (Boehringer Ingelheim)
11.1.1 GST (Boehringer Ingelheim) Company Detail
11.1.2 GST (Boehringer Ingelheim) Business Overview
11.1.3 GST (Boehringer Ingelheim) Pet Stem Cells Introduction
11.1.4 GST (Boehringer Ingelheim) Revenue in Pet Stem Cells Business (2018-2023)
11.1.5 GST (Boehringer Ingelheim) Recent Development
11.2 EquiCord
11.2.1 EquiCord Company Detail
11.2.2 EquiCord Business Overview
11.2.3 EquiCord Pet Stem Cells Introduction
11.2.4 EquiCord Revenue in Pet Stem Cells Business (2018-2023)
11.2.5 EquiCord Recent Development
11.3 VetStem Biopharma
11.3.1 VetStem Biopharma Company Detail
11.3.2 VetStem Biopharma Business Overview
11.3.3 VetStem Biopharma Pet Stem Cells Introduction
11.3.4 VetStem Biopharma Revenue in Pet Stem Cells Business (2018-2023)
11.3.5 VetStem Biopharma Recent Development
11.4 AVSC
11.4.1 AVSC Company Detail
11.4.2 AVSC Business Overview
11.4.3 AVSC Pet Stem Cells Introduction
11.4.4 AVSC Revenue in Pet Stem Cells Business (2018-2023)
11.4.5 AVSC Recent Development
11.5 Boyalife
11.5.1 Boyalife Company Detail
11.5.2 Boyalife Business Overview
11.5.3 Boyalife Pet Stem Cells Introduction
11.5.4 Boyalife Revenue in Pet Stem Cells Business (2018-2023)
11.5.5 Boyalife Recent Development
11.6 Taiwan Pet Valley Advance Biotech Co.,Ltd
11.6.1 Taiwan Pet Valley Advance Biotech Co.,Ltd Company Detail
11.6.2 Taiwan Pet Valley Advance Biotech Co.,Ltd Business Overview
11.6.3 Taiwan Pet Valley Advance Biotech Co.,Ltd Pet Stem Cells Introduction
11.6.4 Taiwan Pet Valley Advance Biotech Co.,Ltd Revenue in Pet Stem Cells Business (2018-2023)
11.6.5 Taiwan Pet Valley Advance Biotech Co.,Ltd Recent Development
11.7 Tianjin Bion Medical
11.7.1 Tianjin Bion Medical Company Detail
11.7.2 Tianjin Bion Medical Business Overview
11.7.3 Tianjin Bion Medical Pet Stem Cells Introduction
11.7.4 Tianjin Bion Medical Revenue in Pet Stem Cells Business (2018-2023)
11.7.5 Tianjin Bion Medical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
GST (Boehringer Ingelheim)
EquiCord
VetStem Biopharma
AVSC
Boyalife
Taiwan Pet Valley Advance Biotech Co.,Ltd
Tianjin Bion Medical
*If Applicable.